key: cord-0927171-vg35wjal authors: Reis, Paulo Eduardo Ocke; Lima, Marcos Cesar Braga title: Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? date: 2020-05-20 journal: Jornal vascular brasileiro DOI: 10.1590/1677-5449.200057 sha: af69d1051daf55fbaef5f5fdb237871e26c1602d doc_id: 927171 cord_uid: vg35wjal Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA(2)DS(2)-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality. Since infection by COVID-19 was first described, the severe respiratory syndrome associated with the disease has caused rapid increases in admissions to intensive care units (ICUs) and elevated mortality of a group of patients. 1 During a pandemic, it is necessary to avoid saturation of health systems, both public and private, and in particular of ICUs. The principal relevant finding in the lungs is presence of platelet thrombi and fibrin in small arterial vessels, which fits perfectly with a clinical scenario of coagulopathy. 2 Since there is no consensus-approved treatment in this situation and considering the possibility of thrombosis associated with infection by coronavirus in certain cases, recently-acquired experience and findings of still-embryonic scientific studies has shown that effective anticoagulation can prevent or reverse the prothrombotic state in some patients. 2,3 We have observed that, coincidentally, the group of patients who respond poorly to the COVID-19 infection ( Figure 1 ) 4 and die are the same patients whose CHA 2 DS 2 -VASc scores indicate risk of stroke, transitory ischemic episode, peripheral emboli, and pulmonary thromboembolism (Table 1) . 5, 6 According to this score, a patient is considered high risk if they score 2 points or more, intermediate risk if they score 1, and low risk if they do not have risk factors. 6 Our proposal, therefore, is to add 1 point to the CHA 2 DS 2 -VASc score (Table 1) for patients who have COVID-19 and use the new score to indicate prophylactic anticoagulation for patients with a high risk of thrombosis according to the score, in phase 2 of the disease ( Table 2 ). The objective is to prevent the patient's condition from worsening because of thromboembolic problems, avoiding the need for ICU admission and mechanical ventilation. 7 The idea is to proceed in a similar manner as with risk of thromboses and emboli according to the existing scores and initiate prophylaxis to attempt to avert occurrence of events that have contributed to the worsening clinical status of these patients. [1] [2] [3] In this communication, the authors propose modifying the scoring of the CHA 2 DS 2 -VASc score and studying its validity, with the objective of reducing the number of critically patients who progress to phase 3. Desde a primeira descrição da infecção por COVID-19, a síndrome respiratória grave associada à doença levou ao aumento rápido de admissões em unidades de tratamento intensivo (UTIs) e à alta mortalidade de um grupo de pacientes 1 . Em uma pandemia, é preciso evitar a saturação do sistema de saúde tanto público quanto privado, em especial das UTIs. O principal achado com relevância nos pulmões é a presença de trombos plaquetários e fibrina em pequenos vasos arteriais, enquadrando-se perfeitamente no contexto clínico da coagulopatia 2 . Como não há um tratamento aprovado em consenso neste cenário e tendo em vista a possibilidade de trombose associada à infecção pelo coronavírus em determinados casos, a experiência adquirida recentemente e estudos científicos ainda embrionários têm mostrado que uma anticoagulação efetiva poderia prevenir ou reverter o estado pró-trombótico de alguns pacientes 2,3 . Observamos que, coincidentemente, o grupo de pacientes que evoluem mal da infecção por COVID-19 (Figura 1) 4 e morrem são os mesmos pacientes do escore CHA 2 DS 2 -VASc com risco para acidente vascular cerebral, episódio isquêmico transitório, embolia periférica e tromboembolismo pulmonar (Tabela 1) 5,6 . Por esse escore, o paciente é considerado de alto risco se a pontuação for 2 ou mais, de risco intermediário se a pontuação for 1 e de baixo risco se não tiver fatores de risco 6 . A nossa proposta, portanto, é incluir 1 ponto adicional no escore CHA 2 DS 2 -VASc (Tabela 1) para pacientes portadores de COVID-19 e usar o novo escore para indicar a anticoagulação profilática nos pacientes com alto risco de trombose pelo escore, na fase 2 da doença (Tabela 2). Desse modo, busca-se evitar a piora do paciente por problemas tromboembólicos, bem como a necessidade de internação em UTI e de ventilação mecânica 7 . A ideia é agir de forma similar ao risco de tromboses e embolias pelos escores conhecidos e iniciar a profilaxia para tentar evitar a ocorrência do que tem contribuído para o agravamento do quadro clínico desses pacientes [1] [2] [3] Clinical features of patients infected with 2019 novel coronavirus in Whuam Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv; 2020 Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic Coronavírus: quais as chances de morrer por causa da covid-19. Brasil: BBC News CHADS 2 e CHA 2 DS 2 VASc como preditores de fonte cardioembólica em prevenção secundária cerebrovascular Time trends in use of the CHADS 2 and CHA 2 DS 2 VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Clinical features of patients infected with 2019 novel coronavirus in Whuam Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv; 2020 Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic Coronavírus: quais as chances de morrer por causa da covid-19. Brasil: BBC News CHADS 2 e CHA 2 DS 2 VASc como preditores de fonte cardioembólica em prevenção secundária cerebrovascular Time trends in use of the CHADS 2 and CHA 2 DS 2 VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up E-mail: vascular@pauloocke.com.br; ockereis@yahoo.com Informações sobre os autores PEOR -MD; PhD; Especialista em Cirurgia Vascular e Endovascular Professor Adjunto de Cirurgia Vascular Contribuições dos autores Concepção e desenho do estudo: PEOR, MCBL Análise e interpretação dos dados: PEOR, MCBL Coleta de dados: PEOR Redação do artigo: PEOR, MCBL Revisão crítica do texto: PEOR, MCBL Aprovação final do artigo*: PEOR, MCBL Análise estatística: MCBL Responsabilidade geral pelo estudo *Todos os autores leram e aprovaram a versão final submetida ao J Vasc Bras